Ontology highlight
ABSTRACT: Introduction:
This study aimed to investigate whether mononucleotide polymorphisms of the angiotensinogen gene at promoter were associated with the blood-pressure-lowering response to telmisartan treatment.Materials and methods:
After a two-week single-blind placebo run-in period, 148 patients with mild-to-moderate primary hypertension received monotherapy with 80 mg/day of telmisartan and then were followed up for eight weeks. The -6A/G and -20A/C polymorphisms of the angiotensinogen gene at promoter were determined through polymerase chain reaction and restriction fragment length polymorphsim analysis. The relationship between these polymorphisms and changes in blood pressure was observed and evaluated after eight weeks of treatment.Results:
There were no signific
SUBMITTER: Gong HT
PROVIDER: S-EPMC6362516 | biostudies-literature | 2019 Jan-Mar
REPOSITORIES: biostudies-literature